Skip to content

A study on Sowbhagya Sundi in the management of Eri Gunmam (Acid Peptic Disease)

Clinical Evaluation of siddha herbal formulation "Sowbhagya Sundi" in the treatment of Eri Gunmam (Acid Peptic Disease) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056341
Enrollment
30
Registered
2023-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: SOWBHAGYA SUNDI: 1.5 grams bds for 48 days Control Intervention1: NIL: NIL

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient who are having symptoms of Eri Gunmam is burning sensation in stomach , colic pain, increased salivation, flatulence, Burping, headache, diarrhoea. (Any of 3 symptoms) 2.Patient who are willing to sign informed consent form 3.Patient who are willing to give blood samples before & after treatment

Exclusion criteria

Exclusion criteria: Known case of , Gastric CA Liver disorders Pancreatitis History of taking medicine for other aliments Cardiac disease Pregnancy & Lactation Abnormal curvature of thoracic vertebra

Design outcomes

Primary

MeasureTime frame
Primary outcome is mainly assessed by comparing the reduction of clinical symptoms before & after treatment by using Gastrointestinal symptoms rating scale (GSRS)Timepoint: 18 MONTHS

Secondary

MeasureTime frame
Secondary outcome is assessed by the disease related to Age, Sex, Dietary habits, Socio economic status, Family history etcTimepoint: 18 MONTHS

Countries

India

Contacts

Public ContactDr N Deepa

National Institute of siddha

dr.vetha@gmail.com9894782366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026